BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi TD, Wu YZ, Jia ZC, Zou LY, Zhou W. Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J Gastroenterol 2004; 10(13): 1902-1906 [PMID: 15222033 DOI: 10.3748/wjg.v10.i13.1902] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ganesan M, Krutik VM, Makarov E, Mathews S, Kharbanda KK, Poluektova LY, Casey CA, Osna NA. Acetaldehyde suppresses the display of HBV-MHC class I complexes on HBV-expressing hepatocytes. Am J Physiol Gastrointest Liver Physiol 2019;317:G127-40. [PMID: 31141391 DOI: 10.1152/ajpgi.00064.2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
2 Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8 + T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions. J I 2010;184:287-95. [DOI: 10.4049/jimmunol.0902761] [Cited by in Crossref: 143] [Cited by in F6Publishing: 139] [Article Influence: 11.0] [Reference Citation Analysis]
3 Lin Y, Dong Y, Gao Y, Shi R, Li Y, Zhou X, Liu W, Li G, Qi Y, Wu Y. Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis. J Immunol Res 2021;2021:8899674. [PMID: 33490292 DOI: 10.1155/2021/8899674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ganesan M, Wang W, Mathews S, Makarov E, New-Aaron M, Dagur RS, Malo A, Protzer U, Kharbanda KK, Casey CA, Poluektova LY, Osna NA. Ethanol attenuates presentation of cytotoxic T-lymphocyte epitopes on hepatocytes of HBV-infected humanized mice. Alcohol Clin Exp Res 2021. [PMID: 34773268 DOI: 10.1111/acer.14740] [Reference Citation Analysis]
5 Brandt AAML, Rodrigues-da-Silva RN, Lima-Junior JC, Alves CR, de Souza-Silva F. Combining Well-Tempered Metadynamics Simulation and SPR Assays to Characterize the Binding Mechanism of the Universal T-Lymphocyte Tetanus Toxin Epitope TT830-843. Biomed Res Int 2021;2021:5568980. [PMID: 34285916 DOI: 10.1155/2021/5568980] [Reference Citation Analysis]
6 Brinck-Jensen NS, Vorup-Jensen T, Leutscher PD, Erikstrup C, Petersen E. Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV. BMC Immunol 2015;16:65. [PMID: 26526193 DOI: 10.1186/s12865-015-0127-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Hu XB, Yue QH, Ouyang HF, Chen YZ, Xu XQ, Yin W, Wei SH, Zhang XQ, Mu SJ. Immune response to fused core protein of hepatitis C virus and truncated tetanus toxin peptides in mice. Arch Virol 2010;155:1097-105. [PMID: 20473626 DOI: 10.1007/s00705-010-0692-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005;4:599-608. [PMID: 15934864 DOI: 10.1517/14740338.4.3.599] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 6.2] [Reference Citation Analysis]
9 Li J, Bao M, Ge J, Ren S, Zhou T, Qi F, Pu X, Dou J. Research progress of therapeutic vaccines for treating chronic hepatitis B. Hum Vaccin Immunother 2017;13:986-97. [PMID: 28118084 DOI: 10.1080/21645515.2016.1276125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wang S, Han Q, Zhang G, Zhang N, Li Z, Chen J, Lv Y, Li N, Xing F, Tian N, Zhu Q, Liu Z. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase. Int Immunopharmacol 2011;11:406-11. [PMID: 21182997 DOI: 10.1016/j.intimp.2010.12.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
11 Yang FQ, Rao GR, Wang GQ, Li YQ, Xie Y, Zhang ZQ, Deng CL, Mao Q, Li J, Zhao W, Wang MR, Han T, Chen SJ, Pan C, Tan DM, Shang J, Zhang MX, Zhang YX, Yang JM, Chen GM. Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy. World J Gastroenterol 2017; 23(2): 306-317 [PMID: 28127204 DOI: 10.3748/wjg.v23.i2.306] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
12 Maman Y, Blancher A, Benichou J, Yablonka A, Efroni S, Louzoun Y. Immune-induced evolutionary selection focused on a single reading frame in overlapping hepatitis B virus proteins. J Virol. 2011;85:4558-4566. [PMID: 21307195 DOI: 10.1128/jvi.02142-10] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
13 Wang S, Han Q, Zhang N, Chen J, Liu Z, Zhang G, Li Z. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice. Immunol Lett 2010;127:143-9. [PMID: 19883689 DOI: 10.1016/j.imlet.2009.10.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
14 Rajčáni J, Szathmary S. Peptide Vaccines: New Trends for Avoiding the Autoimmune Response. TOIDJ 2018;10:47-62. [DOI: 10.2174/1874279301810010047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Cao W, Qiu Z, Zhu T, Li Y, Han Y, Li T. CD8+ T cell responses specific for hepatitis B virus core protein in patients with chronic hepatitis B virus infection. J Clin Virol 2014;61:40-6. [PMID: 25049205 DOI: 10.1016/j.jcv.2014.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Askari A, Hassanshahi GH, Ghalebi SR, Jafarzadeh A, Mohit M, Hajghani M, Kazemi Arababadi M. Intensity of HLA-A2 Expression Significantly Decreased in Occult Hepatitis B Infection. Jundishapur J Microbiol. 2014;7:e10298. [PMID: 25371796 DOI: 10.5812/jjm.10298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Zhang JB, Chen SY, Yang ZQ, Li TR, Chen A, Wu YZ. Comprehensive analysis of the quantity of epitope-specific cytotoxic T lymphocytes in chronic viral hepatitis B infection. Shijie Huaren Xiaohua Zazhi 2004; 12(5): 1069-1072 [DOI: 10.11569/wcjd.v12.i5.1069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Liu HG, Chen WW, Fan ZP, Yang HY, Shi M, Zhang Z, Luan SS, Zhang H, Lu P, Tien P. The high prevalence of the I27 mutant HBcAg18-27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope. Clin Immunol. 2007;125:337-345. [PMID: 17900990 DOI: 10.1016/j.clim.2007.06.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
19 Choga WT, Anderson M, Zumbika E, Phinius BB, Mbangiwa T, Bhebhe LN, Baruti K, Kimathi PO, Seatla KK, Musonda RM, Bell TG, Moyo S, Blackard JT, Gaseitsiwe S. In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana. Viruses 2020;12:E731. [PMID: 32640609 DOI: 10.3390/v12070731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]